Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company (BMY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Want Income and Growth? This Simple 3-ETF Portfolio Does Both

Income investors often face a difficult choice. The choice is whether to chase high yields and sacrifice growth or focus on capital appreciation and settle for minimal income. But in today’s market, where volatility remains high, many investors are looking for a more balanced approach. Dividend-focused ETFs offer a compelling middle ground. This three-ETF portfolio combines the right mix of funds to help provide steady income while still participating in long-term market upside.

The Schwab U.S. Dividend Equity ETF (SCHD) is one of the most popular dividend ETFs. It tracks the Dow Jones U.S. Dividend 100 Index, focusing on ...

Fundamentals

See More
  • Market Capitalization, $K 117,056,520
  • Shares Outstanding, K 2,036,474
  • Annual Sales, $ 48,194 M
  • Annual Income, $ 7,054 M
  • EBIT $ 12,645 M
  • EBITDA $ 16,656 M
  • 60-Month Beta 0.26
  • Price/Sales 2.46
  • Price/Cash Flow 7.15
  • Price/Book 6.39

Options Overview Details

View History
  • Implied Volatility 32.27% (+2.47%)
  • Historical Volatility 22.12%
  • IV Percentile 63%
  • IV Rank 33.40%
  • IV High 55.70% on 04/10/25
  • IV Low 20.52% on 12/31/25
  • Expected Move (DTE 5) 1.62 (2.81%)
  • Put/Call Vol Ratio 1.77
  • Today's Volume 43,378
  • Volume Avg (30-Day) 17,828
  • Put/Call OI Ratio 0.77
  • Today's Open Interest 641,441
  • Open Int (30-Day) 609,414
  • Expected Range 55.87 to 59.10

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 31 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate 1.46
  • Number of Estimates 10
  • High Estimate 1.59
  • Low Estimate 1.39
  • Prior Year 1.80
  • Growth Rate Est. (year over year) -18.89%

Price Performance

See More
Period Period Low Period High Performance
1-Month
56.91 +1.00%
on 03/20/26
62.89 -8.60%
on 03/02/26
-3.18 (-5.24%)
since 02/20/26
3-Month
52.06 +10.41%
on 01/05/26
62.89 -8.60%
on 03/02/26
+3.29 (+6.07%)
since 12/19/25
52-Week
42.52 +35.18%
on 10/29/25
62.89 -8.60%
on 03/02/26
-2.94 (-4.87%)
since 03/20/25

Most Recent Stories

More News
Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)

In the U.S., FDA approval establishes Opdivo in combination with doxorubicin, vinblastine and dacarbazine (AVD) as the first immunotherapy combination approved for adult and pediatric...

BMY : 57.48 (-1.08%)
Want Income and Growth? This Simple 3-ETF Portfolio Does Both

In today’s highly volatile market, this simple 3-ETF portfolio combines both steady income and long-term upside.

MO : 64.47 (-0.92%)
AAPL : 247.99 (-0.39%)
AVGO : 310.51 (-2.92%)
CVX : 201.73 (+0.14%)
VZ : 49.98 (+1.01%)
$SPX : 6,506.48 (-1.51%)
JPM : 286.56 (-0.49%)
JNJ : 235.37 (-0.94%)
SCHD : 30.39 (-0.65%)
ABBV : 205.07 (-0.56%)
BMY : 57.48 (-1.08%)
MSFT : 381.87 (-1.84%)
Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026

Bristol Myers Squibb (NYSE: BMY) will announce results for the first quarter of 2026 on Thursday, April 30, 2026. Company executives will review financial results with the investment community...

BMY : 57.48 (-1.08%)
1 S&P 500 Stock Worth Your Attention and 2 We Question

1 S&P 500 Stock Worth Your Attention and 2 We Question

KO : 74.75 (-1.06%)
BMY : 57.48 (-1.08%)
IQV : 166.07 (-0.24%)
Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma

Study marks the first positive Phase 3 study for mezigdomide and the second positive Phase 3 study for the Bristol Myers Squibb CELMoD program

BMY : 57.48 (-1.08%)
U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis

Significantly more patients treated with once-daily, oral Sotyktu achieved an ACR20 response compared with placebo at Week 16 in the pivotal Phase 3 POETYK PsA-1 and POETYK PsA-2 clinical...

BMY : 57.48 (-1.08%)
Q4 Earnings Outperformers: Bristol-Myers Squibb (NYSE:BMY) And The Rest Of The Branded Pharmaceuticals Stocks

Q4 Earnings Outperformers: Bristol-Myers Squibb (NYSE:BMY) And The Rest Of The Branded Pharmaceuticals Stocks

BMY : 57.48 (-1.08%)
Bristol Myers Squibb Announces Dividend

Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has declared a quarterly dividend of sixty-three cents ($0.63) per share on the $0.10 par value common stock of the...

BMY : 57.48 (-1.08%)
Is Bristol-Myers Squibb Stock Underperforming the Nasdaq?

Though Bristol-Myers Squibb has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

$NASX : 21,647.61 (-2.01%)
LLY : 906.70 (-1.18%)
BMY : 57.48 (-1.08%)
SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

Izalontamab brengitecan (Iza-bren) met its dual primary endpoints of progression free survival (“PFS”) and overall survival (“OS”) in an interim analysis of a Phase 3 trial (NCT06382142) conducted...

BMY : 57.48 (-1.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Bristol-Myers Squibb is a one of the leading global specialty biopharmaceutical companies focused on the development of treatments targeting serious diseases like cancer, inflammatory, immunologic, cardiovascular or fibrotic diseases. Backed by its blockbuster immuno-oncology drug, Opdivo, Bristol-Myers...

See More

Key Turning Points

3rd Resistance Point 60.01
2nd Resistance Point 59.28
1st Resistance Point 58.38
Last Price 57.48
1st Support Level 56.74
2nd Support Level 56.01
3rd Support Level 55.11

See More

52-Week High 62.89
Last Price 57.48
Fibonacci 61.8% 55.11
Fibonacci 50% 52.70
Fibonacci 38.2% 50.30
52-Week Low 42.52

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.